Even if evidence suggests that targeting the Hsc/Hsp70complexmight have pleiotropic effects, it is believed that both profoldingand antidegradation strategies could be therapeutically interestesting.For that, small molecules that target components of the Hsc/Hsp70system can either block mutant CFTR degradation or promote its foldingand therefore have potential applications as CF therapeutics. This evidence concerns the gene FUT1 and cystic fibrosis.